Our strategic focus is to complete the pivotal Phase 3 clinical trial of EryDex, called NEAT (Neurologic Effects of EryDex on Subjects with A-T), to evaluate the safety and efficacy of EryDex for the treatment of Ataxia-Telangiectasia (A-T). A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder with currently no approved therapeutic treatments in any global market for this rare pediatric disease.
Quince has dosed the first patient and is actively enrolling participants for our global Phase 3 NEAT study. Patients with A-T interested in participating can learn more about the NEAT study criteria and locations by visiting Clinicaltrials.gov here.
The U.S. Food and Drug Administration granted Fast Track designation for our EryDex System for the treatment of patients with A-T, underscoring the high unmet medical need as there are currently no approved therapeutic treatments for A-T.